These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26547914)

  • 1. Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study.
    Serpell M; Tripathi S; Scherzinger S; Rojas-Farreras S; Oksche A; Wilson M
    Patient; 2016 Feb; 9(1):35-46. PubMed ID: 26547914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain.
    Conaghan PG; Serpell M; McSkimming P; Junor R; Dickerson S
    Patient; 2016 Aug; 9(4):359-71. PubMed ID: 27314487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study.
    Gallagher AM; Leighton-Scott J; van Staa TP
    Clin Ther; 2009 Aug; 31(8):1707-15. PubMed ID: 19808129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec) in post-traumatic pain.
    Correa-Illanes G; Roa RG; B Piñeros JL; Ferrer FT; Adriasola VR
    Pain Manag; 2014 May; 4(3):181-90. PubMed ID: 24835268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pain therapy in the elderly:7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study].
    Wahle K; Krings D; Schwenke K
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():25-31. PubMed ID: 23678668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
    Schmid-Grendelmeier P; Pokorny R; Gasser UE; Richarz U
    Curr Med Res Opin; 2006 Mar; 22(3):501-9. PubMed ID: 16574034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
    Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G
    Curr Med Res Opin; 2014 Aug; 30(8):1579-87. PubMed ID: 24689806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
    Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
    J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
    Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management.
    O'Brien T; Ahn JS; Chye R; Le B; Lu H; Olarte G; Palladini M; Salti A; Shao YY; Yaakup H; Buemio KC; Colin CG; Hadjiat Y
    J Opioid Manag; 2019; 15(2):147-158. PubMed ID: 31343716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.